Compare · NVO vs TLX
NVO vs TLX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Telix Pharmaceuticals Limited (TLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TLX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.92B, about 51.4x TLX ($3.81B).
- Over the past year, NVO is down 36.6% and TLX is down 40.1% - NVO leads by 3.4 points.
- TLX has been more active in the news (19 items in the past 4 weeks vs 6 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 5 for TLX).
- Company
- Novo Nordisk A/S
- Telix Pharmaceuticals Limited
- Price
- $43.88+3.99%
- $11.26+2.41%
- Market cap
- $195.92B
- $3.81B
- 1M return
- +20.30%
- +21.68%
- 1Y return
- -36.63%
- -40.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 19
- Recent ratings
- 25
- 5
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest TLX
- TLX101-Px (Pixlumi®) MAA Accepted in Europe
- OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
- Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
- SEC Form 6-K filed by Telix Pharmaceuticals Limited
- ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
- SEC Form 6-K filed by Telix Pharmaceuticals Limited
- SEC Form 6-K filed by Telix Pharmaceuticals Limited
- Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
- SEC Form 6-K filed by Telix Pharmaceuticals Limited
- SEC Form 6-K filed by Telix Pharmaceuticals Limited